Cerebrolysin — Complete Research Guide (2026)

Last updated 2026-06-25

What is Cerebrolysin?

Cerebrolysin is a peptide preparation derived from purified porcine (pig) brain tissue, marketed as a neurotrophic/neuroprotective agent and used in some countries (notably Russia, Eastern Europe, China, and parts of Asia) for stroke, dementia, and traumatic brain injury.

It is NOT approved by the FDA or EMA. The human evidence base includes numerous randomized controlled trials and Cochrane systematic reviews, but results are mixed and, for acute ischaemic stroke, largely neutral.

Because it is a complex biological mixture without Western regulatory approval, quality and standardization outside its approved markets are uncertain.

How does Cerebrolysin work?

Cerebrolysin contains low-molecular-weight peptides and free amino acids proposed to mimic endogenous neurotrophic factors, potentially supporting neuronal survival, plasticity, and repair.

The precise active components and clinical mechanism remain incompletely defined, and proposed neurotrophic effects have not translated into consistent clinical benefit. [INFOGRAPHIC: Proposed neurotrophic action of Cerebrolysin peptides]

What does the research say about Cerebrolysin?

• In the CARS randomized controlled trial (n=208) of moderate-to-severe stroke, Cerebrolysin was associated with better upper-limb motor recovery (Action Research Arm Test) at day 90 versus placebo. ^[2]
• In a randomized double-blind trial in vascular dementia (n about 240), Cerebrolysin improved cognitive (ADAS-cog+) and clinician-rated global outcomes at 24 weeks compared with placebo. ^[4]
• In a 24-week randomized Alzheimer's disease trial testing three dosages, Cerebrolysin improved global clinical outcome (CIBIC+) versus placebo. ^[5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Cerebrolysin for acute ischaemic stroke — Ziganshina LE et al., Cochrane Database Syst Rev 2020. (systematic review (7 RCTs, ~1601))
• [2] Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial — Muresanu DF et al., Stroke 2016. (RCT (n=208))
• [3] Cerebrolysin for vascular dementia — Cui S et al., Cochrane Database Syst Rev 2019. (systematic review)
• [4] Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial — Guekht AB et al., J Stroke Cerebrovasc Dis 2011. (RCT (n about 240))
• [5] Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages — Alvarez XA et al., Eur J Neurol 2011. (RCT (three dosages))

Dosing context

Trials typically administered Cerebrolysin as daily intravenous infusions (commonly 10-30 mL/day) over multi-week courses, sometimes in repeated cycles, always in clinical settings.

These protocols describe study designs only, not a recommendation; the product is unapproved in many jurisdictions and should not be self-administered.

Side effects & safety profile

Importantly, the 2020 Cochrane systematic review of acute ischaemic stroke (7 RCTs, ~1601 participants) found that Cerebrolysin probably has little or no beneficial effect on death or dependency, and flagged moderate-quality evidence of a possible increase in non-fatal serious adverse events; the overall conclusion did not demonstrate clinical benefit.

Reported adverse effects in trials are generally mild (e.g., injection-site reactions, dizziness, agitation), but the signal of increased non-fatal serious adverse events in the stroke review warrants caution.

As a porcine brain-derived biological not approved by the FDA/EMA, it carries theoretical concerns about immunogenicity and product standardization, and much of the positive dementia evidence comes from small or industry-linked trials rated as weak.

Stacking & combinations

In trials it has been given alongside standard care or with agents such as donepezil, but combination use is investigational and does not have established added-benefit or safety data.

Finding Cerebrolysin vendors

User reviews

Frequently asked questions

References

1. [1] Cerebrolysin for acute ischaemic stroke — Ziganshina LE et al., Cochrane Database Syst Rev 2020. PMID: 32662068. View sourceStudy: systematic review (7 RCTs, ~1601)Found no convincing clinical benefit for acute ischaemic stroke and moderate-quality evidence of a possible rise in non-fatal serious adverse events.
2. [2] Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial — Muresanu DF et al., Stroke 2016. PMID: 26564102. View sourceStudy: RCT (n=208)Reported improved upper-limb motor function at day 90 with Cerebrolysin versus placebo in moderate-to-severe stroke.
3. [3] Cerebrolysin for vascular dementia — Cui S et al., Cochrane Database Syst Rev 2019. PMID: 31710397. View sourceStudy: systematic reviewConcluded the supporting evidence base is weak and better-quality trials are needed to confirm any effect in vascular dementia.
4. [4] Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial — Guekht AB et al., J Stroke Cerebrovasc Dis 2011. PMID: 20656516. View sourceStudy: RCT (n about 240)Reported improved cognitive and global outcomes at 24 weeks with Cerebrolysin versus placebo, and good tolerability.
5. [5] Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages — Alvarez XA et al., Eur J Neurol 2011. PMID: 20500802. View sourceStudy: RCT (three dosages)Reported improved global clinical outcome versus placebo over 24 weeks in Alzheimer's disease.

Related peptides